COL4A3BP Antibody
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-30902
Key Product Details
Species Reactivity
Human
Applications
Western Blot
Label
Unconjugated
Antibody Source
Polyclonal Rabbit IgG
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Synthetic peptide derived from human COL4A3BP protein
Clonality
Polyclonal
Host
Rabbit
Isotype
IgG
Scientific Data Images for COL4A3BP Antibody
Western Blot: COL4A3BP Antibody [NBP3-30902] -
Western Blot: COL4A3BP Antibody [NBP3-30902] - Western blot using CERTL antibody (Cat. No. NBP3-30902) on HT-29 cell lysate (28 ug/lane). Primary antibody used at 10ug/ml. Secondary antibody, mouse anti-rabbit HRP, used at 1:50k.Applications for COL4A3BP Antibody
Application
Recommended Usage
Western Blot
: 5-10 ug/ml
Application Notes
.
Formulation, Preparation, and Storage
Purification
Ammonium sulfate precipitation
Formulation
Phosphate buffered saline
Preservative
0.08% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at -20C. Avoid freeze-thaw cycles.
Background: COL4A3BP
Alternate Names
Ceramide transfer protein, CERTFLJ20597, CERTL, collagen type IV alpha-3-binding protein, collagen, type IV, alpha 3 (Goodpasture antigen) binding protein, Goodpasture antigen-binding protein, GPBPSTARD11ceramide transporter, hCERT, lipid-transfer protein CERTL, StARD11, StAR-related lipid transfer (START) domain containing 11, StAR-related lipid transfer protein 11, START domain containing 11, START domain-containing protein 11
Gene Symbol
CERT1
Additional COL4A3BP Products
Product Specific Notices for COL4A3BP Antibody
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...